Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel

Avelino, Camila Uanne Resende; Cardoso, Rafael Marques; Aguiar, Suzana Sales de; Silva, Mário Jorge Sobreira da

doi:10.1590/s1806-37132015000004367

Cited by 20 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A cross-sectional design was adopted in 55.6% (n=10) of the studies. Non-controlled prospective, "before and after" studies assessed QoL before and after chemotherapy 9,14 , before three cycles of chemotherapy 26 , before and after lung resectioning 21,22 , before and after physiotherapy 20 , before starting treatment and two and four months after the first evaluation and/or the beginning of treatment 27 .…”

Section: Resultsmentioning

confidence: 99%

“…The most frequently adopted was specific for people with cancer, EORTC QLQ-C30, although it was used in less than half of the articles. Its LC-13 complementary module was used in two studies 15,26 because it is specific for lung cancer, evaluating QoL for the particular symptoms of this disease. It is therefore recommended to combine these scales.…”

Section: Discussionmentioning

confidence: 99%

“…QoL was eva luated before and after chemotherapy 9,14,26,27 with varying assessment frequencies in patients with cancer stages I to IV.…”

Section: (9)mentioning

confidence: 99%

See 2 more Smart Citations

Quality of life of patients with lung cancer: A scoping review

Mota

Júnior

Pereira

et al. 2019

Rev. bras. geriatr. gerontol.

View full text Add to dashboard Cite

Objective: To characterize scientific publications on the quality of life of people with lung cancer in order to explore current knowledge of the subject, with emphasis on assessment instruments and methodological aspects. Method: A scoping type literature review was performed. Articles were sought in the databases of the Virtual Health Library, in an integrative manner, with the descriptors: Quality of life and Lung Neoplasms, with no date of publication or language restrictions (n=138). The selection of articles was based on inclusion and exclusion criteria defined in the study proposal. Results: We included 18 publications published between 2006 and 2017, the majority (n = 10) of which had a cross-sectional design. Eight different instruments were used to evaluate the quality of life of patients with lung cancer, four of which were specific for people with cancer. There was a prevalence of the use of the European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire - EORTC QLQ-C30 (n=8). Prospective studies (n=8) assessed quality of life before and after chemotherapy, physical therapy or pulmonary resection. The studies adopted different methodologies and provided conflicting results of quality of life. Cross-sectional studies with comparatively healthy subjects found an inferior quality of life for people with lung cancer. Conclusion: The scoping review contributed to the identification of the multiple evaluated instruments, both generic and specific. It found a lack of homogeneity in the methodological approaches of the studies. Further prospective studies with a specific instrument and methodological standardization to evaluate the quality of life of people with lung cancer are recommended.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life of patients with lung cancer: A scoping review

Mota

Júnior

Pereira

et al. 2019

Rev. bras. geriatr. gerontol.

View full text Add to dashboard Cite

show abstract

“…Though systemic chemotherapy has associated side-effects, multiple studies have shown improved survival and QoL in patients with IIIB/IV NSCLC. [101][102][103][104] Though this review will not cover chemotherapy in any depth, several studies have shown survival, QoL, and symptomatic benefits from cytotoxic chemotherapy regimens including vinblastine, docetaxel, vinorelbine, gemcitabine, and pemetrexed. [105][106][107][108][109][110] Addressing concurrent chemoradiation, in 191 patients with stage III NSCLC, adding concurrent radiation improved survival (3 months) and maintained QoL, at the expense of increased hospital admissions.…”

Section: Benefits Of Palliative Care In Lung Cancermentioning

confidence: 99%

Palliative Care in Lung Cancer: A Review

Bade

Silvestri

2016

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung cancer patients are at high risk of suffering due to severe and refractory symptoms, concomitant respiratory comorbidity, frequent disease progression, and treatment that can worsen and compromise quality of life. Palliative care (PC) has shown multiple benefits to cancer patients such as better quality of life, higher patient and family satisfaction, improved disease understanding, less symptom burden, fewer depressive symptoms, less aggressive end of life care, and even improved survival with early implementation. For these reasons, multiple societies have recognized PC as an essential component of lung cancer care, and early PC is recommended for patients with metastatic disease or refractory symptoms. Unfortunately, utilization of PC is both low and often near the end of life, increasing risk for suffering. Misconceptions about PC often underlie delayed referral to PC. This review summarizes the literature for utilization of PC in lung cancer and focuses on patient benefits, misconceptions, barriers, and implementation.

show abstract

“…One such study involves the use of a lectin, Maackia amurensis agglutinin (MAA), as an adjuvant and shows its efficacy in different cancers (Lalli et al, 2015). Other studies show combinations of different drugs with paclitaxel to enhance its efficacy, like dasatinib (Xiao et al, 2015) and carboplatin (Avelino et al, 2015).…”

Section: Clinical Trialsmentioning

confidence: 99%

From Lab to Pharmacy Shelves: The Story of a Plant Derived Anticancer Drug, "Paclitaxel"

2015

J. Bioresource Manage.

View full text Add to dashboard Cite

Paclitaxel (Taxol ®) is a highly praised anticancer drug, known for its efficiency in treating different cancers. It belongs to a class of compounds called taxanes that are derived from the plants of the genus Taxus. This drug is now FDA approved, but there was a time when the name Taxol was less known to the scientific world. Taxol, being a unique molecule in its structure, properties and mechanism of action, has undergone more than 30 years of trials, and faced a lot of hurdles to leave the bench of a laboratory and reach the shelves of a pharmacy. This review focuses on the story of Taxol, how it began and how it achieved the status of Paclitaxel.

show abstract

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel

Cited by 20 publications

References 27 publications

Quality of life of patients with lung cancer: A scoping review

Quality of life of patients with lung cancer: A scoping review

Palliative Care in Lung Cancer: A Review

From Lab to Pharmacy Shelves: The Story of a Plant Derived Anticancer Drug, "Paclitaxel"

Contact Info

Product

Resources

About